First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations with Unresectable Stage III or IV Melanoma: CheckMate 401.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Combination Therapies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined